NCT05617755
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 14 versions: 12 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Stopped Trial terminated Sponsor's reason: Active patients have been rolled over to a separate LTFU study.
- Eligibility criteria expanded, about 16 words
- Study completion date changed from estimate of Feb 2027 to Oct 26, 2026
- Study Identification, Study Status, Oversightv12
- Minor Enrollment target: estimated 60 to confirmed 19
- Study sites: 10 to 8
- Minor Trial status: Recruiting to Active, Not Recruiting
- Primary completion date: Dec 2024 to Sep 30, 2024
- Site details revised at 10 of 10 sites
- Notable Primary completion date: Mar 2024 to Dec 2024v8
Show 6 earlier versionsHide 6 earlier versions
- Minor Study sites: 8 to 10v7
- Notable Eligibility criteria expanded, about 4 words
- Study sites: 5 to 8
- Minor Study sites: 2 to 5v5
- Minor Study sites: 1 to 2v4
- Minor Start date changed from estimate of Nov 2022 to Nov 29, 2022v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of adverse events and dose limiting toxicities (DLTs)
Timeframe: Up to 2 years post treatment
Maximal tolerated dose of AB-1015
Timeframe: Up to 21 days
Secondary (3)
Number of AB-1015 cells
Evidence of anti-tumor activity
Co-expression of ALPG and MSLN targets on tumor cells
Arms and interventions
AB-1015Experimental
Patients receive fludarabine and cyclophosphamide intravenously on days -5 to -3. Patients receive a single dose of AB-1015 intravenously on day 0.
Biologicals: AB-1015
Sites
8 sites in 1 country